COVID-19 has changed life as we know it. Bloodworks is committed to the fight.
COVID-19 Convalescent plasma (CCP) remains the best treatment option for COVID-19 until a vaccine becomes available.
Since April, 2020, Bloodworks’ CCP Program has helped patients recover from COVID-19 and contributed to science’s understanding of how the human body responds to the novel coronavirus through research, blood collection, and transfusion medicine.
Yet another way we’re saving lives in local communities.
Please only submit the qualification form one time per person.
Duplicate entries may cause delays in processing your submission.
How do you fit in?
About the Program
WE ARE ALL IN THIS TOGETHER. Bloodworks has partnered with the Center for Disease Control (CDC), University of Washington, and local public health authorities to further blood research and treatment of COVID-19.
Under the leadership of our transfusion medicine and patient services experts, Bloodworks collects antibody-rich COVID-19 convalescent plasma (CCP) from donors who are fully recovered from COVID-19 for local hospitals to treat patients currently fighting the disease.
With the continued rise of COVID-19 cases locally and around the world, patients in our community have an ongoing need for CCP transfusion. Bloodworks will continue to supply CCP for patient treatment as long as it is needed.
Bloodworks is also supporting national efforts to collect CCP for the production of immunoglobulin concentrates and units for the national stockpile to contribute to national efforts to use plasma for various future COVID-19 treatments.
In addition, our Research Institute has undertaken ground-breaking studies to determine how blood type impacts COVID-19 risk and unravel other mysteries.
- Rebecca Haley, MD
- Kirsten Alcorn, MD
- Sumi Paranjape, PhD
- Aaron Posey, Director, Bloodworks Bio